https://www.selleckchem.com/pr....oducts/abemaciclib.h
To report the safety and efficacy of a novel cell-injection therapy using cultured human corneal endothelial cells (hCECs) for endothelial failure conditions via the report of the long-term clinical data of 5-years postoperative in a 'first-in-man' clinical trial group. Prospective observational study. This study involved 11 eyes of 11 patients with pseudophakic endothelial failure conditions who underwent hCEC-injection therapy between December 2013 and December 2014. All patients underwent follow-up examinations at 1-, 4-, 12-, an
Like
Comment
Share
